Newsbenzinga
Regeneron Says Newly Approved Drug Shows Sustained Efficacy In Halting Rogue Bone Growth
· Published
Article summary
Regeneron's Pasatru shows sustained efficacy in halting new bone growth and reducing flare-ups in adults with FOP in an 84-week trial.
An excerpt from the original article.
Comments —
Loading comments…